Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...

Related Keywords

Copenhagen ,Køavn ,Denmark ,Kamstrup ,Sjæand ,Langsted ,Syddanmark ,Switzerland ,Japan ,Beijing ,China ,United States ,Canada ,Canadian ,American ,America ,Nathalie Altermatt ,Jay Bradner ,Sabine Borngr ,Karsten Kleine ,Rebekka Schnell ,Simon Goldsborough ,Loren Kalm ,Birgit Masjost ,Kirti Pandey ,Yvette Petillon ,Sileia Urech ,Bruno Eschli ,Coll Cardiol ,Matt Sause ,Roche Group ,Genentech ,European Atherosclerosis Society ,Canadian Cardiovascular Society ,Amgen ,National Lipid Association ,Breakthrough Devices Program ,European Society Of Cardiology ,Heart Society ,Drug Administration ,Journal Of The American Heart Association ,Roche Diagnostics Tina Quant ,Breakthrough Device Designation ,European Society ,Beijing Heart Society ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Cardiovascular Risk Thresholds ,Estimated Lipoprotein ,Free Low ,Density Lipoprotein ,American Heart ,European Heart Journal ,Copenhagen General Population ,